Shifting reimbursement models and mounting site-of-care pressures are pushing cancer programs toward ambulatory expansion. Leaders discuss why building flexible, lower-cost outpatient infrastructure now protects both margins and patient access, and how to sequence capital investments despite ongoing uncertainty surrounding payer policy and value-based reimbursement structures ahead.